The Surface Issue #4, June edition, was sent to all PSOLVE+ members by email on Tuesday, June 1, and can be accessed online here. This edition covers:
- Safety and efficacy of secukinumab in a single, 300mg/2mL pre-filled syringe
- Risk of malignancy with up to five years of secukinumab treatment
- Reviewing the evidence for over-the-counter supplements in dermatology
- Telogen effluvium patient demographics during the pandemic
- North American Contact Dermatitis Group patch testing with sodium disulfite
- Hereditary angioedema in the emergency department
To view all issues of The Surface, go to psolve.org/the-surface
